140 related articles for article (PubMed ID: 17571586)
1. [Treatment with voriconazole for invasive fungal infection during chemotherapy for leukemia: doses and plasma concentration of voriconazole in children].
Fukushima K; Fujisawa M; Nakajima D; Matsunaga T; Hagisawa S; Kurosawa H; Sugita K; Arisaka O
Rinsho Ketsueki; 2007 May; 48(5):402-6. PubMed ID: 17571586
[TBL] [Abstract][Full Text] [Related]
2. Voriconazole drug monitoring in the management of invasive fungal infection in immunocompromised children: a prospective study.
Soler-Palacín P; Frick MA; Martín-Nalda A; Lanaspa M; Pou L; Roselló E; de Heredia CD; Figueras C
J Antimicrob Chemother; 2012 Mar; 67(3):700-6. PubMed ID: 22190607
[TBL] [Abstract][Full Text] [Related]
3. Differences in voriconazole trough plasma concentrations per oral dosages between children younger and older than 3 years of age.
Shima H; Miharu M; Osumi T; Takahashi T; Shimada H
Pediatr Blood Cancer; 2010 Jul; 54(7):1050-2. PubMed ID: 20146339
[TBL] [Abstract][Full Text] [Related]
4. Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients.
Lutsar I; Roffey S; Troke P
Clin Infect Dis; 2003 Sep; 37(5):728-32. PubMed ID: 12942409
[TBL] [Abstract][Full Text] [Related]
5. Voriconazole plasma monitoring.
Pasqualotto AC; Shah M; Wynn R; Denning DW
Arch Dis Child; 2008 Jul; 93(7):578-81. PubMed ID: 18252755
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic drug monitoring of voriconazole after intravenous administration in infants and children with primary immunodeficiency.
Gerin M; Mahlaoui N; Elie C; Lanternier F; Bougnoux ME; Blanche S; Lortholary O; Jullien V
Ther Drug Monit; 2011 Aug; 33(4):464-6. PubMed ID: 21743382
[TBL] [Abstract][Full Text] [Related]
7. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes.
Pascual A; Calandra T; Bolay S; Buclin T; Bille J; Marchetti O
Clin Infect Dis; 2008 Jan; 46(2):201-11. PubMed ID: 18171251
[TBL] [Abstract][Full Text] [Related]
8. Clinical application of voriconazole concentrations in the treatment of invasive aspergillosis.
Howard A; Hoffman J; Sheth A
Ann Pharmacother; 2008 Dec; 42(12):1859-64. PubMed ID: 19017830
[TBL] [Abstract][Full Text] [Related]
9. Voriconazole concentrations and outcome of invasive fungal infections.
Miyakis S; van Hal SJ; Ray J; Marriott D
Clin Microbiol Infect; 2010 Jul; 16(7):927-33. PubMed ID: 19845698
[TBL] [Abstract][Full Text] [Related]
10. Impact of therapeutic drug monitoring of voriconazole in a pediatric population.
Brüggemann RJ; van der Linden JW; Verweij PE; Burger DM; Warris A
Pediatr Infect Dis J; 2011 Jun; 30(6):533-4. PubMed ID: 21127454
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of voriconazole after oral administration of single and multiple doses in African grey parrots (Psittacus erithacus timneh).
Flammer K; Nettifee Osborne JA; Webb DJ; Foster LE; Dillard SL; Davis JL
Am J Vet Res; 2008 Jan; 69(1):114-21. PubMed ID: 18167096
[TBL] [Abstract][Full Text] [Related]
12. Prophylactic administration of voriconazole with two different doses for invasive fungal infection in children and adolescents with acute myeloid leukemia.
Sano H; Kobayashi R; Hori D; Kishimoto K; Suzuki D; Yasuda K; Kobayashi K
J Microbiol Immunol Infect; 2018 Apr; 51(2):260-266. PubMed ID: 27329132
[TBL] [Abstract][Full Text] [Related]
13. Determination of saliva trough levels for monitoring voriconazole therapy in immunocompromised children and adults.
Michael C; Bierbach U; Frenzel K; Lange T; Basara N; Niederwieser D; Mauz-Körholz C; Preiss R
Ther Drug Monit; 2010 Apr; 32(2):194-9. PubMed ID: 20216120
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of concentration of voriconazole in aqueous humor after topical and oral administration in horses.
Clode AB; Davis JL; Salmon J; Michau TM; Gilger BC
Am J Vet Res; 2006 Feb; 67(2):296-301. PubMed ID: 16454636
[TBL] [Abstract][Full Text] [Related]
15. Voriconazole serum concentrations in prophylactically treated acute myelogenous leukaemia patients.
Rüping MJ; Müller C; Vehreschild JJ; Böhme A; Mousset S; Harnischmacher U; Frommolt P; Wassmer G; Drzisga I; Hallek M; Cornely OA
Mycoses; 2011 May; 54(3):230-3. PubMed ID: 19889174
[TBL] [Abstract][Full Text] [Related]
16. Oral voriconazole for empiric antifungal treatment in patients with uncomplicated febrile neutropenia.
Przepiorka D; Buadi FK; McClune B
Pharmacotherapy; 2008 Jan; 28(1):58-63. PubMed ID: 18154475
[TBL] [Abstract][Full Text] [Related]
17. Importance of voriconazole therapeutic drug monitoring in pediatric cancer patients with invasive aspergillosis.
Choi SH; Lee SY; Hwang JY; Lee SH; Yoo KH; Sung KW; Koo HH; Kim YJ
Pediatr Blood Cancer; 2013 Jan; 60(1):82-7. PubMed ID: 22887791
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of voriconazole after oral and intravenous administration to horses.
Davis JL; Salmon JH; Papich MG
Am J Vet Res; 2006 Jun; 67(6):1070-5. PubMed ID: 16740104
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of voriconazole following intravenous and oral administration and body fluid concentrations of voriconazole following repeated oral administration in horses.
Colitz CM; Latimer FG; Cheng H; Chan KK; Reed SM; Pennick GJ
Am J Vet Res; 2007 Oct; 68(10):1115-21. PubMed ID: 17916020
[TBL] [Abstract][Full Text] [Related]
20. A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML).
Vehreschild JJ; Böhme A; Buchheidt D; Arenz D; Harnischmacher U; Heussel CP; Ullmann AJ; Mousset S; Hummel M; Frommolt P; Wassmer G; Drzisga I; Cornely OA
J Infect; 2007 Nov; 55(5):445-9. PubMed ID: 17822770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]